10-Q: Veeva Systems Reports Strong Q2 Growth, Settles IQVIA Litigation

Veeva Systems Inc. announced robust financial results for the second quarter and first half of fiscal year 2026, marked by significant revenue and profit increases, alongside the resolution of its long-standing litigation with IQVIA.

Summary

• Total revenues for the three months ended July 31, 2025, increased by 17% to $789.1 million, up from $676.2 million in the prior year period.
• Subscription services revenue grew 17% to $659.2 million for the quarter, while professional services and other revenue increased 13% to $129.9 million.
• Net income for the quarter rose 17.1% to $200.3 million, or $1.19 per diluted share, compared to $171.0 million, or $1.04 per diluted share, in the same quarter last year.
• For the six months ended July 31, 2025, total revenues increased 17% to $1,548.1 million, with subscription services revenue up 18% to $1,294.0 million.
• Net cash provided by operating activities for the six months ended July 31, 2025, was $1,115.6 million, a 30.3% increase from $856.4 million in the prior year period.
• Cash, cash equivalents, and short-term investments totaled $6.4 billion as of July 31, 2025.
• Veeva and IQVIA entered into a settlement agreement on August 13, 2025, resolving all ongoing litigations with no damages paid by either party, resulting in a $31 million accrual for success fees to law firms.
• The company is actively migrating its Veeva CRM customers to its proprietary Vault CRM platform, with the Salesforce platform agreement for Veeva CRM expiring on September 1, 2025, followed by a wind-down period until September 1, 2030.
• R&D Solutions revenue is expected to continue increasing as a percentage of both subscription services and total revenues in the future.

Sentiment

Score: 8

Explanation: The company delivered strong financial results with significant revenue and profit growth, particularly in subscription services. The resolution of the IQVIA litigation removes a major overhang. While strategic transitions like the Vault CRM migration and evolving AI regulations present risks, the overall financial health and strategic positioning are robust, indicating positive momentum.

Positives

• Strong revenue growth of 17% for both the three and six months ended July 31, 2025, demonstrating continued market demand for solutions.
• Subscription services revenue, the primary revenue driver, increased by 17% for the quarter and 18% for the six-month period, indicating healthy recurring revenue streams.
• Net income and diluted EPS showed significant year-over-year growth, with net income up 17.1% for the quarter and 28.8% for the six-month period.
• Operating cash flow increased substantially by 30.3% to $1,115.6 million for the six months, bolstered by the 'One Big Beautiful Bill Act' (OBBBA) which restored immediate expensing of R&D expenditures.
• Successful settlement of the long-standing IQVIA litigation, eliminating a significant legal overhang and associated uncertainties, with no damages paid by either party.
• R&D Solutions continue to be a strong growth area, with revenue increasing by $62 million for the quarter and $119 million for the six months, and expected to grow as a percentage of total revenues.
• The company maintains a robust liquidity position with $6.4 billion in cash, cash equivalents, and short-term investments, providing financial flexibility.

Negatives

• General and administrative expenses for the three months ended July 31, 2025, increased significantly by 56% to $95.8 million, primarily due to a $31 million litigation settlement-related charge.
• Deferred revenue decreased from $1,273.9 million as of January 31, 2025, to $1,107.7 million as of July 31, 2025, which may not be an accurate indicator of future revenue but is noted.
• The migration of Veeva CRM customers to Vault CRM carries risks of business disruptions, potential customer loss to competitors (e.g., Salesforce), and challenges in supporting increased user volume.
• The effective tax rate increased primarily due to the indirect effects of the OBBBA, despite increased excess tax benefits related to equity compensation.

Risks

• Security breaches or unauthorized access to customer data could lead to diminished demand, significant liabilities, and reputational damage, with cyberattack risks potentially elevated due to geopolitical conflicts.
• The markets are highly competitive, with new entrants and existing competitors (e.g., Salesforce, IQVIA, Dassault Systèmes) offering alternative solutions, potentially leading to reduced sales or margins.
• Failure of newer solutions, including AI technologies, to achieve successful adoption by new and existing customers could adversely affect revenue growth rates.
• Revenue is relatively concentrated among a small number of key customers (top 10 customers accounted for 28% of total revenues in FY25), making the company vulnerable to the loss or non-renewal of these customers.
• Defects or disruptions in solutions could result in diminished demand, revenue reduction, increased operational costs, and substantial liability.
• The migration of Veeva CRM customers to Vault CRM could cause business disruptions, lead to customer loss to competitors, and adversely affect operating results if unsuccessful.
• Nearly all revenues are generated from the life sciences industry, making the company susceptible to adverse factors affecting this industry, such as regulatory changes, drug pricing reforms, industry consolidation, and funding environment shifts.
• Uncertain macroeconomic and geopolitical factors (e.g., inflation, currency fluctuations, interest rates, conflicts like the Russian invasion of Ukraine and the Middle East) may negatively impact business and financial results.
• Difficulty attracting and retaining highly skilled employees in a competitive talent market could adversely affect business and increase expenses.
• Reliance on third-party providers (e.g., Amazon Web Services, Salesforce) for computing infrastructure and network connectivity exposes the company to risks of service disruptions and potential liability.
• Increasingly complex U.S. and international data privacy and information security regulations (e.g., GDPR, CCPA, China's PIPL, Washington's My Health My Data Act) impose compliance costs, may reduce demand, and subject the company to significant liabilities.
• Incorporating AI in solutions or other uses of AI may result in reputational harm and increased liability due to concerns about privacy, security, efficacy, bias, or evolving regulations (e.g., EU AI Act).
• Potential for lawsuits for infringement or misappropriation of third-party intellectual property, which could result in significant damages, ongoing royalty payments, or restrictions on service offerings.
• Acquisitions of other companies or technologies could divert management's attention, result in dilution to stockholders, disrupt operations, and may not yield anticipated benefits.
• The company's status as a Delaware public benefit corporation (PBC) introduces unique legal obligations, requiring directors to balance stockholder interests with other stakeholder interests and public benefit purpose, which may lead to legal uncertainty or decisions not maximizing short-term stockholder value.
• The company's estimate of its total addressable market (TAM) may prove inaccurate, and there is no assurance that the business will serve a significant portion of this market.

Future Outlook

R&D Solutions revenues are expected to increase as a percentage of both subscription services revenues and total revenues in the future. The 'One Big Beautiful Bill Act' (OBBBA) is expected to increase cash flows from operating activities for the fiscal year ending January 31, 2026, and in future periods. The company anticipates operating expenses to increase due to employee compensation-related costs, continued investment in product offerings, and marketing program costs. The company will continue to invest in its Veeva AI initiative, which will add AI to applications across all major areas.

Management Comments

• Our CEO reviews financial information on a consolidated basis for purposes of allocating resources and evaluating financial performance, indicating a unified strategic approach.
• Management finds it useful to exclude stock-based compensation, amortization of purchased intangibles, and litigation settlement-related charges from internal management reporting to assess operating expenses and resource allocations.
• Management believes existing cash, cash equivalents, and short-term investments will be sufficient to meet working capital and capital expenditure needs over at least the next 12 months.

Industry Context

Veeva Systems operates as the leading provider of industry cloud solutions for the global life sciences industry, a sector characterized by rapid regulatory changes, consolidation, and evolving technological demands. The company's focus on R&D and Commercial Solutions aligns with the industry's need for faster product development, efficient commercialization, and regulatory compliance. The increasing adoption of AI technologies, as highlighted by Veeva's AI initiative, reflects a broader industry trend towards leveraging advanced analytics for improved efficiency and decision-making. The ongoing migration from legacy CRM platforms to specialized cloud solutions, such as Veeva's Vault CRM, indicates a shift away from general-purpose platforms like Salesforce towards industry-specific, integrated ecosystems. The impact of drug pricing regulations and geopolitical factors underscores the complex external environment influencing IT spending within the life sciences sector.

Comparison to Industry Standards

• Veeva's 17% revenue growth for the quarter and 18% subscription services growth are strong, particularly given the size of the company, and compare favorably to many mature enterprise software providers. For instance, while Salesforce (a competitor in CRM) has seen varying growth rates, Veeva's specialized focus allows for targeted expansion within the life sciences vertical.
• The gross margin for subscription services at 86-87% is indicative of a highly efficient cloud software business, aligning with or exceeding benchmarks set by top-tier SaaS companies like Adobe or Microsoft's cloud segments.
• The significant increase in operating cash flow (30.3%) demonstrates robust cash generation, a key indicator of financial health and operational efficiency, often sought after by investors in the tech sector.
• The successful settlement of the IQVIA litigation removes a significant legal burden, a positive development that differentiates Veeva from companies embroiled in prolonged, costly legal battles, allowing for clearer focus on core business and innovation.
• The strategic shift to Vault CRM, while presenting transition risks, positions Veeva to offer a fully integrated, proprietary platform, potentially enhancing competitive advantage against generalist CRM providers like Salesforce, which has announced its own life sciences CRM development in collaboration with IQVIA.

Corporate Governance

Legal Proceedings

• Veeva and IQVIA entered into a settlement agreement on August 13, 2025, resolving all ongoing litigations (IQVIA Inc. v. Veeva Systems Inc. No. 2:17-cv-00177 and No. 2:19-cv-15517).
• Under the settlement, neither party will pay damages to the other, and all claims and counterclaims have been dismissed with prejudice.
• Accrued approximately $31 million as of July 31, 2025, for success fees due to law firms under partial contingency fee arrangements related to the IQVIA litigations.

Stakeholder Impact

• **Shareholders**: Positive financial results, strong cash flow, and resolution of major litigation are beneficial. However, the PBC status means directors balance financial interests with other stakeholders, which might not always maximize short-term shareholder value. Stock price volatility remains a risk.
• **Customers**: Continued investment in R&D and new solutions (including AI) promises enhanced product offerings. The migration to Vault CRM could cause short-term disruptions but aims for a more integrated and compliant long-term solution. Data privacy and security measures are critical for customer trust.
• **Employees**: Expansion of headcount in R&D, sales, and marketing indicates growth opportunities. The 'Work Anywhere' policy offers flexibility. Competition for skilled employees and potential changes in equity award perception could impact retention.
• **Partners**: The company's reliance on third-party computing infrastructure providers (e.g., Amazon Web Services) and the wind-down of the Salesforce platform agreement for CRM will impact these relationships. New partnerships may be sought for AI and other technologies.
• **Communities**: The public benefit purpose includes creating high-quality employment opportunities in operating communities, aligning with broader ESG expectations.

Next Steps

• Continue the migration of Veeva CRM customers to the Vault CRM application.
• Focus research and development efforts on platforms, adding new features and applications, and enhancing existing solutions.
• Invest in the Veeva AI initiative to integrate AI into applications across clinical, regulatory, safety, quality, medical, and commercial areas.
• Monitor and adapt to evolving global data privacy and cybersecurity regulations, including those related to AI and cross-border data transfers.
• Manage the wind-down period of the Salesforce platform agreement for Veeva CRM until September 1, 2030.
• Evaluate the impact of new accounting pronouncements, ASU 2023-09 and ASU 2024-03, on future disclosures.

Key Dates

Recommendation

Veeva Systems Inc. demonstrates robust financial performance with strong revenue and net income growth, particularly in its high-margin subscription services. The successful resolution of the long-standing IQVIA litigation removes a significant legal and financial uncertainty, allowing management to focus entirely on strategic initiatives. The company's strategic migration to its proprietary Vault CRM platform, coupled with significant investments in AI and R&D, positions it for continued leadership and innovation within the specialized life sciences cloud market. While risks such as customer concentration and regulatory changes exist, Veeva's strong balance sheet, consistent cash generation, and clear strategic direction make it a compelling 'strong buy' for long-term investors seeking exposure to a dominant player in a critical industry.

Keywords

Life Sciences Cloud, CRM, R&D Solutions, Commercial Solutions, Vault CRM, SEC 10-Q, Software as a Service, Healthcare Technology, Biotech Software, Pharmaceutical Software, Data Cloud, Regulatory Compliance, Clinical Trials, Salesforce Platform, AI in Healthcare